RxDoctor Payments Data

Mohammed Pourakbar, DO

Internal Medicine · Independence, MONPI 1730193541

Payments from drug & device makers

$6,723in general payments, 2019–2025

Across 412 payments — averaging $16.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$470
  • Lilly USA, LLC$421
  • Sanofi-aventis U.S. LLC$342
  • Pfizer$328
  • Novo Nordisk$290
  • plus $4K from 54 others

What the payments were for

  • Speaking & faculty fees$701%
  • Food & beverage$6,65399%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)71$1,189
AstraZeneca29$470
Lilly USA, LLC27$421
Sanofi-aventis U.S. LLC26$342
Pfizer24$328
Novo Nordisk19$290
GSK20$286
Amgen(2 entities)15$269
Novartis18$265
Antares Pharma, Inc.13$194
Sumitomo Pharma America, Inc.10$187
Amarin Pharma, Inc.10$149
Astellas Pharma US Inc9$144
E.r. Squibb & Sons, L.L.C.8$133
Boehringer Ingelheim8$125
Abbott7$125
Takeda Pharmaceuticals U.S.A., Inc.7$111
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$110
Otsuka America Pharmaceutical, Inc.5$105
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$99
Merck7$91
Boston Scientific2$79
Sunovion Pharmaceuticals Inc.4$77
Sanofi1$70
Mylan Specialty L.p.4$60
Axsome Therapeutics, Inc.3$59
Teva Pharmaceuticals USA, Inc.4$57
Sanofi Pasteur Inc.4$56
Radius Health, Inc.2$53
Exact Sciences3$46
Eisai Inc.2$45
Dexcom, Inc.2$44
Bayer2$40
Cequr Corporation1$36
Vanda Pharmaceuticals Inc.1$36
Inspire Medical Systems, Inc.2$33
Biohaven Pharmaceutical Holding Company Ltd.2$31
Johnson & Johnson2$28
Medtronic1$27
Shire North American Group Inc2$27
Vertex1$26
Endo Pharmaceuticals Inc.2$24
Neurelis, Inc.1$24
Esperion Therapeutics, Inc.1$23
Corcept Therapeutics1$23
Viatris Specialty LLC1$20
Phathom Pharmaceuticals, Inc.1$20
Azurity Pharmaceuticals, Inc.1$19
Biogen1$19
Upsher-smith Laboratories LLC1$18
Adlon Therapeutics L.p.1$18
Evofem Biosciences, Inc.1$17
Electromed, Inc.1$16
Kowa Pharmaceuticals America, Inc.1$16
Hologic Sales And Service, LLC1$16
Clarus Therapeutics Inc.1$15
Aytu Biopharma, Inc.1$15
IBSA Pharma Inc.1$15
Organogenesis Inc.1$13
Genentech USA, Inc.1$13

How this compares

$6,723 in reported general payments places this provider in the 90th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$167,933
Medicare patients
244
Services billed
9,389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban128$159,826
JanuviaSitagliptin Phosphate67$83,482
XareltoRivaroxaban75$66,381
OzempicSemaglutide45$50,493
JardianceEmpagliflozin37$42,279
TradjentaLinagliptin38$29,887
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog32$20,339
ArexvyRsvpref3 Antigen/As01e/Pf71$18,773
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$16,928
TrulicityDulaglutide15$16,346
AbrysvoRsv Vacc, Pref A And Pref B/Pf52$15,348
Humalog Kwikpen U-200Insulin Lispro23$11,513
Novolog FlexpenInsulin Aspart72$11,062
MyrbetriqMirabegron14$10,103
Atorvastatin Calcium752$7,076

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$328$175,174180 claims
MerckJanuvia$91$83,48267 claims
Boehringer IngelheimJardiance, Tradjenta$125$72,16575 claims
Johnson & JohnsonXarelto$28$66,38175 claims
Novo NordiskOzempic$290$50,49345 claims
GSKArexvy$286$18,77371 claims
Lilly USA, LLCTrulicity$421$16,34615 claims
Astellas Pharma US IncMyrbetriq$144$10,10314 claims
AstraZenecaSymbicort$470$6,46921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Independence

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →